Live Breaking News & Updates on Adaptimmune

Stay updated with breaking news from Adaptimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adaptimmune Therapeutics PLC: Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma

- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint ....

Pennsylvania , United-states , Philadelphia , Dennis-williams , Julip-miller , Dana-lynch , Stage-development , Exchange-commission , Corporate-communications , Drug-administration , Corporate-affairs , Nasdaq

Adaptimmune Therapeutics PLC: Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel Overall response rate ....

Pennsylvania , United-states , Philadelphia , Vancouver , British-columbia , Canada , America , Briana-van , Julip-miller , Dana-lynch , Sarcoma-foundation-of-america , Washington-university-school-of-medicine

Adaptimmune Therapeutics PLC: Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK

Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 -GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma ....

Pennsylvania , United-states , Philadelphia , Adrian-rawcliffe , Julip-miller , Dana-lynch , Exchange-commission , Corporate-communications , Nasdaq , Corporate-affairs , United-newsfile-corp , Chief-executive

Adaptimmune Therapeutics PLC: Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers Further clinical development planned ....

Canada , United-kingdom , Colombo , Western , Sri-lanka , Texas , United-states , Philadelphia , Pennsylvania , Emaase , Schleswig-holstein , Germany

Adaptimmune Therapeutics PLC: Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas

- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) Responses occurred across subgroups, with greater response ....

Pennsylvania , United-states , Philadelphia , America , American , Brandi-felser , Julip-miller , Exchange-commission , American-society-of-clinical-oncology , Sarcoma-foundation-of-america , Nasdaq , Corporate-affairs